• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals (NQ: ALNY )

    245.32 +5.17 (+2.15%)
    Streaming Delayed Price Updated: 3:56 PM EDT, Jun 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,585,657
    Open 237.70
    Bid (Size) 245.25 (4)
    Ask (Size) 245.40 (9)
    Prev. Close 240.15
    Today's Range 236.50 - 249.33
    52wk Range 141.97 - 242.00
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
    On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21, 
    Via Benzinga
    Topics Stocks
    Exposures US Equities

    Performance

    YTD
    +25.85%
    +25.85%
    1 Month
    +63.48%
    +63.48%
    3 Month
    +61.43%
    +61.43%
    6 Month
    +28.31%
    +28.31%
    1 Year
    +28.21%
    +28.21%

    More News

    Read More
    Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
    Via Benzinga
    (ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
    Via Benzinga
    How Is The Market Feeling About Alnylam Pharmaceuticals?
    Via Benzinga
    Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
    Via InvestorPlace
    Exposures Product Safety
    Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
    Via InvestorPlace
    Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
    Via Benzinga
    Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
    Via Investor's Business Daily
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Masters In Trading - Saturday, June 22
    Via Talk Markets
    Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
    Via Benzinga
    $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Alnylam Issues 2023 Corporate Responsibility Report
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
    Via Benzinga
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.